Historical source coverage
25 selected records with a cited source date in 2012. This archive is selective and does not imply continuous monitoring or complete historical coverage.
Clinical trials · Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT00426153 at 2026-07-30T22:14:20.912Z. Its registry update date was 2012-11-21, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Literature metadata · Ipamorelin
PeptideScanner retained PubMed bibliographic metadata for PMID 10373343 at 2026-07-30T22:15:26.481Z. PubMed recorded a metadata revision date of 2012-11-15 and an Entrez history date of 1999-06-22. PeptideScanner associated this retained record with the identity slug ipamorelin. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata · Epitalon
PeptideScanner retained PubMed bibliographic metadata for PMID 12195242 at 2026-07-30T22:15:26.486Z. PubMed recorded a metadata revision date of 2012-11-15 and an Entrez history date of 2002-08-27. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata · Epitalon
PeptideScanner retained PubMed bibliographic metadata for PMID 12500162 at 2026-07-30T22:15:26.487Z. PubMed recorded a metadata revision date of 2012-11-15 and an Entrez history date of 2002-12-25. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata · Epitalon
PeptideScanner retained PubMed bibliographic metadata for PMID 12500171 at 2026-07-30T22:15:26.487Z. PubMed recorded a metadata revision date of 2012-11-15 and an Entrez history date of 2002-12-25. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata · Epitalon
PeptideScanner retained PubMed bibliographic metadata for PMID 16634527 at 2026-07-30T22:15:26.490Z. PubMed recorded a metadata revision date of 2012-11-15 and an Entrez history date of 2006-04-26. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Clinical trials · Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT01695109 at 2026-07-30T22:14:20.912Z. Its registry update date was 2012-09-27, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Literature metadata · Teriparatide
PeptideScanner retained PubMed bibliographic metadata for PMID 22986396 at 2026-07-30T22:15:26.556Z. PubMed recorded a metadata revision date of 2012-09-18 and an Entrez history date of 2012-09-19. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Regulatory · Linaclotide
DailyMed lists Structured Product Labeling version 2 for the reviewed Linaclotide label family with a published date of 2012-09-11. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory · Linaclotide
The official Drugs@FDA dataset lists original submission 1 for NDA 202811 with status AP dated 2012-08-30, and names linaclotide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Literature metadata · Exenatide
PeptideScanner retained PubMed bibliographic metadata for PMID 22753275 at 2026-07-30T22:15:26.545Z. PubMed recorded a metadata revision date of 2012-08-23 and an Entrez history date of 2012-07-04. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Clinical trials · Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT01078805 at 2026-07-30T22:14:20.917Z. Its registry update date was 2012-06-26, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Clinical trials · Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT01056549 at 2026-07-30T22:14:20.917Z. Its registry update date was 2012-06-22, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Clinical trials · Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT00004895 at 2026-07-30T22:14:20.917Z. Its registry update date was 2012-06-06, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Regulatory · Tesamorelin
The Federal Register published notice 2012-10808, attributed to FDA and its parent HHS department, on 2012-05-04. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; EGRIFTA,” and PeptideScanner's exact reviewed identity mapping connects the document to Tesamorelin.
Source: Federal Register via GovInfo ↗
Regulatory · Liraglutide
The Federal Register published notice 2012-10517, attributed to FDA and its parent HHS department, on 2012-05-02. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; Victoza,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.
Source: Federal Register via GovInfo ↗
Clinical trials · Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT00171613 at 2026-07-30T22:14:20.909Z. Its registry update date was 2012-04-30, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Clinical trials · Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT01580514 at 2026-07-30T22:14:20.913Z. Its registry update date was 2012-04-19, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Clinical trials · Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT00653757 at 2026-07-30T22:14:20.913Z. Its registry update date was 2012-03-19, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Clinical trials · Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT00257426 at 2026-07-30T22:14:20.913Z. Its registry update date was 2012-02-14, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Literature metadata · Liraglutide
PeptideScanner retained PubMed bibliographic metadata for PMID 20610447 at 2026-07-30T22:15:26.499Z. PubMed recorded a metadata revision date of 2012-02-09 and an Entrez history date of 2010-07-09. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata · Exenatide
PeptideScanner retained PubMed bibliographic metadata for PMID 20436114 at 2026-07-30T22:15:26.497Z. PubMed recorded a metadata revision date of 2012-02-09 and an Entrez history date of 2010-05-04. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Regulatory · Exenatide
The official Drugs@FDA dataset lists original submission 1 for NDA 022200 with status AP dated 2012-01-27, and names exenatide synthetic among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Clinical trials · Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT00805935 at 2026-07-30T22:14:20.915Z. Its registry update date was 2012-01-27, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Regulatory · Leuprolide + 1 more
The Federal Register published notice 2012-1433, attributed to FDA and its parent HHS department, on 2012-01-25. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide.
Source: Federal Register via GovInfo ↗